SCHEMBL21151136

SCHEMBL21151136

O=C(CCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCn1cc(-c2cccc(NC(=O)N3CCC4(CC3)NC(=O)N(c3cccc5ncccc35)C4=O)c2)nn1)ON1C(=O)CCC1=O

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HDAC1 Q13547 3/20 0.33
▸ HDAC6 Q9UBN7 3/20 0.33
▸ HDAC3 O15379 2/20 0.32
▸ NAMPT P43490 2/20 0.32
▸ NPY5R Q15761 2/20 0.31
▸ ABCG2 Q9UNQ0 2/20 0.31
▸ PDGFRB P09619 1/20 0.31
▸ KDR P35968 2/20 0.31
▸ HDAC4 P56524 1/20 0.31
▸ HDAC7 Q8WUI4 1/20 0.31
▸ HDAC2 Q92769 1/20 0.31
▸ HDAC10 Q969S8 1/20 0.31
▸ HDAC11 Q96DB2 1/20 0.31
▸ HDAC8 Q9BY41 1/20 0.31
▸ HDAC9 Q9UKV0 1/20 0.31
▸ HDAC5 Q9UQL6 1/20 0.31
▸ CCNE1 P24864 2/20 0.31
▸ CDK2 P24941 2/20 0.31
▸ TEK Q02763 1/20 0.30
▸ TACR1 P25103 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21151315 0.89 NAMPT (0.35) HDAC1HDAC6HDAC3NAMPTNPY5R
SCHEMBL21150845 0.88 NAMPT (0.34) HDAC1HDAC6HDAC3NAMPTNPY5R
SCHEMBL21151776 0.88 NAMPT (0.34) HDAC1HDAC6HDAC3NAMPTNPY5R
SCHEMBL21151259 0.86 NAMPT (0.34) HDAC1HDAC6HDAC3NAMPTKDR
SCHEMBL21151765 0.86 NAMPT (0.32) NAMPTTACR1
SCHEMBL21151783 0.85 NAMPT (0.33) HDAC1HDAC6HDAC3NAMPTABCG2
SCHEMBL24974528 0.85 MAPK1 (0.33) HDAC1HDAC6NAMPTPDGFRBTACR1
SCHEMBL21150848 0.85 NAMPT (0.34) HDAC1HDAC6HDAC3NAMPTKDR
SCHEMBL21151158 0.85 NAMPT (0.33) HDAC1HDAC6HDAC3NAMPTKDR
SCHEMBL21150858 0.84 NAMPT (0.36) HDAC1HDAC6HDAC3NAMPTNPY5R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11572370-B2 CD16A binding agents and uses thereof BIOHAVEN THERAPEUTICS LTD. (US) 2023-02-07 — — US disclosed
WO-2019136442-A1 CD16A BINDING AGENTS AND USES THEREOF KLEO PHARMACEUTICALS, INC. (US) 2019-07-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11572370-B2 CD16A binding agents and uses thereof FCGR1A, FCGR2A, FCGR3B HDAC1 2698/4885HDAC6 3459/4885HDAC3 2964/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback